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Treatment options for pulmonary arterial hypertension (PAH) have considerably improved in the past few years. Endothelin (ET)-receptor
antagonism has been established as a ﬁrst-line option for the majority of PAH patients. Endothelin-receptor antagonists (ETRAs) comprise
sulfonamide and non-sulfonamide agents with different afﬁnities for ET-receptor subtypes (ETA and ETB), and the focus of development has
shifted from drugs with less selectivity to those with high selectivity. There is ongoing debate as to whether selective or non-selective ET-
receptor antagonism is more beneﬁcial in the treatment of PAH. This paper reviews the current evidence from experimental and clinical
studies obtained from a thorough literature search focusing on the three marketed drugs bosentan, sitaxentan, and ambrisentan.
A clinically meaningful difference among the three approved ETRAs with respect to their ET-receptor selectivity could not be demonstrated
to date. Therefore, in clinical practice, other features are likely to be of greater relevance when considering treatment, such as the potential
for serious drug–drug interactions, convenience of dosing schedule, or rates of limiting side effects. These characteristics bear more relation
to the chemical or pharmacological properties of the drugs than to receptor selectivity itself.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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Introduction
Pulmonary arterial hypertension (PAH) is a group of diseases
characterized by progressive increases in pulmonary vascular
resistance (PVR) and pulmonary arterial pressure (PAP), resulting
in right ventricular failure and premature death.
1,2 A number of
drug classes have been approved for this indication on the basis
of randomized, controlled trials, namely prostanoids (epoproste-
nol, iloprost, and treprostinil), phosphodiesterase-5-inhibitor
(sildenaﬁl), and endothelin (ET)-receptor antagonists (ETRAs)
(bosentan, sitaxentan, and ambrisentan).
3 The ETRA drug class
comprises sulfonamide and non-sulfonamide agents with different
afﬁnities for endothelin-receptor (ET) subtypes, and there are con-
tinuing discussions as to whether selective or non-selective
ET-receptor antagonism is more beneﬁcial in the treatment of
PAH. This paper reviews the current evidence from experimental
and clinical studies obtained from a thorough literature search
using the general search terms ‘endothelin receptor antagonist’
and ‘pulmonary (arterial) hypertension’. Particular focus has been
placed on clinical articles.
Effects of endothelin-1 mediated
via ETA and ETB receptors
The human endothelin (ET) family consists of three 21-amino acid
isopeptides: ET-1, ET-2, and ET-3. Of these, only ET-1 plays an
important physiological and pathophysiological role, especially in
the regulation of vascular tone. ET-1 is released principally from
endothelial cells that line blood vessels, but also from other vascu-
lar and non-vascular cells. Most of its effects are paracrine, the
most striking of which is its extremely potent and long-lasting
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4 In addition, ET-1 is proﬁbrotic and
involved in the pathogenesis of various diseases, including PAH.
Speciﬁcally, ET-1 can induce hypertrophy and hyperplasia in
various cell types,
5 ﬁbroblast proliferation,
6 extracellular matrix
production,
7 inﬂammation,
8 and neuro-humoral stimulation.
9 Fur-
thermore, it stimulates the generation of other local mediators
of vascular tone, including nitric oxide (NO), prostacyclins, and
platelet-activating factors.
10 These factors modulate the effects of
ET-1 in the cardiovascular system through their vasorelaxant
action and anti-proliferative potential.
Circulating plasma ET-1 levels are elevated in atherosclerosis,
arterial hypertension, heart failure, and PAH
11 when compared
with the normal state. Of note, ET-1 plasma levels correlate with
parameters of pulmonary haemodynamics,
12 and predict survival in
patients with untreated PAH.
13
ETA- vs. ETB-mediated effects
Within the mammalian cardiovascular system, ET-1 acts through
two receptor subtypes—ETA and ETB. In the vasculature, ETA
receptors are located on smooth muscle cells (SMCs) and
ﬁbroblasts, whereas ETB receptors are predominantly localized
on endothelial cells and, to a lesser extent, on SMCs, ﬁbroblasts,
and macrophages. Recent data using cultured transfected cell
lines suggest that ETA and ETB receptors can form constitutive het-
erodimers (dimerization theory). Functionally, this means that ETB
receptors expressed on SMCs couple with ETA receptors, and the
former adopt the function of the latter, such that ETB receptors in
heterodimers mediate vasoconstriction similar to ETA receptors.
14
Furthermore, it has been suggested that selective antagonism of
one ET-receptor subtype only may result in compensation by
the other receptor. This experimental hypothesis has been called
‘cross-talk’.
15,16
Under normal physiological conditions, the receptor types have
broadly opposing functions (Figure 1). Activation of ETA receptors
mediates vasoconstriction,
4 proliferation,
17,18 hypertrophy,
5,19 cell
migration,
20 and ﬁbrosis, whereas activation of endothelial ETB
receptors stimulates the release of potent vasodilators (NO and
prostacyclin), which exhibit anti-proliferative properties, and pre-
vents apoptosis.
21 Importantly, ETB receptors on endothelial cells
mediate the clearance of circulating ET-1 in the lungs, kidney,
and liver, with up to 50% of mature ET-1 in healthy subjects and
40% in patients with PAH cleared via pulmonary ETB
receptors.
22 Endothelial cell ETB-receptor activation also inhibits
ET converting enzyme-1, the enzyme that is required to produce
mature ET-1.
23
Alterations in the distribution and number of ETA and ETB
receptors in conditions such as PAH suggest that their roles in
the disease state may differ from those in normal physiology. For
example, there are more ET-1-binding sites in the distal pulmonary
vessels of patients with PAH, and ETB receptors are also
Figure 1 Schematic of the distribution of ETA and ETB receptors in various layers of the vessel wall of a small pulmonary artery in the healthy
state (left) and in PAH (right). In the intima, only ETB receptors are expressed, in the media both ETA and ETB, and in the adventitia only ETA.
In the diseased artery, structural changes (intima structure not intact with schematic illustration of plaque; media with smooth muscle cell
proliferation, adventitia thickened) are evident. In terms of functional changes, the number/density of ET receptors of both types increases
in all vessel layers, however, the ETA receptors to a greater extent.
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24 ETB receptors may not exclusively mediate pulmon-
ary vasodilatation. Because of the effects of a sub-population of
ETB receptors located on SMC and ﬁbroblasts, the spectrum of
possible adverse effects of ETB-receptor stimulation in patients
with pulmonary hypertension includes the induction of vasocon-
striction,
15,25 proliferation,
24,26 and ﬁbrosis.
27
Early suggestions that the endothelium might be dysfunctional,
resulting in diminished expression or loss of function of the ETB
receptors,
28 have recently been challenged by the ﬁndings of
Langleben et al.,
29 who observed intact or only modestly
reduced ETB-mediated clearance of ET-1 in patients with pulmon-
ary hypertension of various aetiologies. The authors concluded
that the ET-1 levels are increased primarily because of excess
synthesis rather than reduced clearance of ET-1.
Receptor selectivity and endothelin
plasma levels
Endothelin-receptor antagonists are usually categorized according
to their selectivity for ETA or ETB receptors. The ETA pharmaco-
logical probe, BQ-123, is considered the benchmark for a selective
ETRA, based on an ETA:ETB binding ratio of 2000:1 in a standard in
vitro assay.
30,31 To some extent, however, the deﬁnition of recep-
tor selectivity is arbitrary, given the wide variation in values
obtained using different experimental systems. For example, the
ETRA ambrisentan has been reported to have an ETA:ETB selectiv-
ity ranging from 29:1 for ET-1-mediated contraction in the rat
aorta
32 to 4000:1 in myocardial membranes.
33
An indication of functional selectivity can be gained from obser-
vations of the effects of different ETRAs on circulating ET-1 levels
in vivo. For example, sitaxentan (in vitro ETA:ETB selectivity
.6500:1) acutely decreases ET-1 levels in patients with chronic
heart failure,
34 indicating that ETB receptors, which play a role in
ET-1 clearance, remain functional. In contrast, bosentan and less-
selective ETA-receptor antagonists (ETA:ETB ratio ,2000:1)
increase plasma ET-1 in healthy volunteers and in patients with
heart failure or PAH (Table 1). Interestingly, signiﬁcant increases
of ET-1 levels occurring 2 h following ingestion have been reported
with ambrisentan (widely reported to be selective for ETA),
suggesting that its functional selectivity may differ from that
observed in vitro.
35 Whether elevated ET-1 levels seen in ETRA-
treated PAH patients have pathophysiological or prognostic signiﬁ-
cance remains unknown.
Experimental evidence
Endothelin-receptor selectivity and its
vasoconstriction and vasodilation effects
Vasodilation is an important goal of therapeutic intervention for
PAH. Theoretically, selective ETA-receptor antagonists should be
more effective in achieving this than non-selective ETA-/ETB-
receptor antagonists, given the role played by ETB receptors in
both vasodilation and ET-1 clearance. In animal models of PAH,
however, positive dilatory effects have been observed with both
selective ETA-receptor blockade and non-selective antagonism
36
(see Supplementary material online).
Since direct evaluation of the pulmonary circulation requires
invasive procedures, the majority of the available data are extrapo-
lated from human studies performed on blood vessels in the sys-
temic circulation.
37,38 Collectively, these studies indicate that: (i)
selective ETA-receptor blockade results in a robust vasodilator
response and increased blood ﬂow; (ii) selective ETB-receptor
blockade results in vasoconstriction and reduced blood ﬂow; and
(iii) co-administration of selective ETA- and ETB-receptor antagon-
ists attenuates the vasodilator response relative to selective
ETA-receptor blockade (see Supplementary material online).
However, although these data provide information regarding the
effects of receptor selectivity on blood vessel tone in general,
they do not provide precise information on how these drugs
work in the pulmonary arterial circulation.
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Table 1 Effects of endothelin receptor antagonists on ET-1 plasma levels in humans
Study Indication Design n Dose Interval Effect on ET-1 level
Bosentan
Kiowski et al.
101 CHF r, pc, db 24 100–200 mg i.v. (single ascending dose) 1 h " .2.0 
Su ¨tsch et al.
102 CHF r, pc, db 36 1000 mg b.i.d. oral 3 h (Day 1) " .2.0 
Chronic 1000 mg b.i.d. 3 h (Day 14) " .1.3 
Weber et al.
103 Healthy volunteers r, pc, db 8 3–2400 mg oral " 2 
10–750 mg i.v. (single ascending doses) " 3 
Williamson et al.
105 PAH o 7 50, 150, and 300 mg i.v. 6 h " 2  (dose dependent)
Hiramoto et al.
106 PAH o 7 62.5 mg (single oral dose) 6 h " 2.0 
Sitaxentan
Givertz et al.
34 CHF o 47 0.5, 3.0, or 6.0 mg/kg 6 h # 0.8 
Ambrisentan
FDA report
35 Healthy volunteers o 7 5 mg (single oral dose) 2 h " 1.6 pg/mL
a
7 10 mg (single oral dose) 2 h " 1.1 pg/mL
a
aPlacebo-subtracted median. CHF, congestive heart failure; db, double-blind; h, hours; i.v., intravenous; o, open; PAH, pulmonary arterial hypertension; pg, picogram; pc, placebo
controlled; r, randomized.
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effects on vascular remodelling
Several studies in animal models document that ETRAs, both non-
selective
39,40 and ETA selective,
41–43 prevent, attenuate, or even
reverse vascular remodelling and/or hypertrophy. For example,
in a rat model, during a 2 week hypoxia exposure, sitaxentan
43
and bosentan
39 signiﬁcantly prevented the increase in PAP, and
prevented the pulmonary vascular remodelling. During a 6 week
hypoxia exposure, both drugs partially reverted pre-established
pulmonary vascular remodelling. Interestingly, sitaxentan,
43 but
not bosentan,
39 prevented the increase in ET-1 levels when treat-
ment was initiated early, with hypoxia. In contrast, late treatment,
2 weeks after initiation of hypoxia, did not affect the established
elevation of ET-1 level.
Endothelin-receptor selectivity
and ﬁbrosis
Extra-vascular anti-mitotic and anti-ﬁbrotic effects of ETRAs may
result in greater efﬁcacy in scleroderma than therapies directed
exclusively at the vasculature.
44–46 Data from animal models
using either ETA-selective or non-selective ETRAs
47–53 demon-
strate an amelioration of ET-1-related effects involving the
reduction of growth factor expression, extracellular matrix
deposition, and matrix metalloproteinase activity.
In vitro data with skin ﬁbroblasts suggested that targeting both
the ETA and the ETB receptors is preferable in order to block col-
lagen type I and III production.
54 However, subsequent in vitro data
using lung ﬁbroblasts indicate that ET-1 induces collagen matrix
contraction through the ETA receptor, but not the ETB receptor.
55
Furthermore, while there is evidence that ETB receptors are linked
to collagen production in vitro, in vivo animal data with ETA antag-
onists have shown that they effectively block the accumulation of
collagen I, III, and IV,
56 normalize pro-collagen I and III mRNA,
49
and abolish the effect of ET-1 on pro-collagen metabolism.
57 Like-
wise, although there is evidence that under certain conditions ET-1
can act as a mitogen in vitro through both ETA- and ETB-receptor
activation,
58 ETB receptors have been shown to inhibit vascular
SMC proliferation in vivo.
59 It has been suggested that ETB recep-
tors may be up-regulated on SMCs and ﬁbroblasts in certain
disease states such as scleroderma lung disease.
60 However, the
spatial distribution of these receptors among different cell types
within the lung microcirculation remains unclear, as does the sig-
niﬁcance of any increased ETB-receptor expression in PAH.
Clinical trials in pulmonary
arterial hypertension patients
ETRAs have been studied in numerous open and several controlled
clinical trials in patients with PAH. The differences between the
...............................................................................................................................................................................
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Table 2 Pharmacological and pharmacokinetic characteristics of approved endothelin-receptor antagonists
Parameter Bosentan Sitaxentan Ambrisentan
Structure Etherocyclic sulfonamide Amidothiophene sulfonamide Diphenyl propionic acid
Selectivity ETA:ETB 30:1 6500:1 4000:1
ET plasma levels after administration "# "
Approved daily dosing 125–250 mg 100 mg 5–10 mg
Titration Yes No Yes
Resorption
Absolute bioavailability 50% 70–100% High (% not reported)
Food effect on resorption No No No
Time to max. plasma concentration (tmax) (h) 3–5 1–4 1.7–3.3
Distribution
Albumin binding (%) .98 .99 99
Metabolism and excretion
Terminal elimination half-life (h) 5.4 10 15
Steady state (days) 3–5 6 3–4
Metabolism Hepatic (CYP) Hepatic (CYP) Hepatic (CYP and
glucuronidation; P-gp)
Cytochromes (CYP) p450 mainly involved CYP 2C9 ", 3A4" CYP 2C9# CYP 3A4", 2C19"
Excretion in urine (%) ,3 50–60 Low
Signiﬁcant drug–drug interactions Sildenaﬁl, glibenclamide, warfain,
and cyclosporin A
Warfarin and cyclosporin A Cyclosporin A
a
EPAR Thelinw
99, EPAR Tracleerw
98, Barst
89. Vatter and Seifert
107, and PI Letairisw.
CYP: " drug induces;# drug inhibits; P-gp, P-glycoprotein.
aNot for sildenaﬁl or warfarin. Note: drug interaction potential of ambrisentan according to Letairisw prescribing information ‘not well characterized’.
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but also linked to other properties, such as pharmacokinetics or
drug–drug interactions. Table 2 provides an overview of the
pharmacological properties of the three available ETRAs. Patient
characteristics and outcomes of the pivotal studies of each agent
are shown in Table 3 and discussed below.
Bosentan
Bosentan is an orally active, non-peptidic, non-selective,
sulphonamide-class ETA/ETB antagonist with twice-daily (b.i.d.)
dosing. It was the ﬁrst ETRA to receive approval for the treatment
of patients with PAH in NYHA functional class III (Europe, USA, and
Canada) and IV (USA and Canada) at a target dose of 125 mg b.i.d.
In two randomized, controlled trials, bosentan was shown to
improve exercise capacity, functional class, haemodynamics, and
time to clinical worsening.
61,62 Additional open-label, long-term
studies in patients with PAH demonstrated persistent efﬁcacy of
bosentan over time and potential for improved survival, compared
with predicted survival.
63,64
Since these ﬁrst pivotal studies, signiﬁcant beneﬁts of bosentan
treatment have been shown in separate studies (’Bosentan
Randomized Trials of Endothelin Antagonist Therapy’: BREATHE)
in children with PAH
65 [BREATHE-3: idiopathic PAH and
congenital heart disease (CHD)], in PAH associated with HIV
66
(BREATHE-4), in patients with PAH and Eisenmenger syndrome
67
(BREATHE-5), and in patients with portopulmonary hypertension.
68
In addition, the ‘Endothelin Antagonist tRial in miLdlY sympto-
matic PAH patients’ (EARLY) was the ﬁrst study speciﬁcally
designed to evaluate the effects of ETRA treatment in 185 PAH
patients in functional class II. Preliminary results from this 6
month trial highlight a signiﬁcant reduction in PVR while the
other primary endpoint, the 6 min walk distance (6MWD), did
not reach statistical signiﬁcance. The secondary endpoint, time
to clinical worsening, showed a signiﬁcant improvement with
bosentan, translating into a 70% risk reduction.
69
In another group of 157 patients with chronic thrombo-embolic
pulmonary hypertension (WHO Group 4), bosentan therapy led
to signiﬁcant reductions in PVR and improved dyspnoea score,
while the 6MWD remained unchanged over the 6 month study
period (‘BosEntan in iNopErable Forms of chronIc Thrombo-
embolic pulmonary hypertension’: BENEFIT).
Ambrisentan
Ambrisentan is an orally active ETA-receptor antagonist belonging
to the propanoic acid class. Although data describing the selectivity
of ambrisentan for the ETA receptor vary between 29:1
32 and
.4000:1,
33 depending on the assay cited, the drug is considered
to be a selective ETA-receptor antagonist.
70,71 In the USA, ambri-
sentan has been approved at a dose of 5–10 mg once daily for
PAH patients with WHO functional class II or III symptoms to
improve exercise capacity and delay clinical worsening. In
Europe, ambrisentan was approved in April 2008 following a
positive opinion from the European Committee for Human
Medicinal Products for the treatment of PAH patients in functional
class II and III.
72
Results are based on a 12 week, blinded-to-dose (1, 2.5, 5, or
10 mg daily) Phase II study
73 (improvements in 6MWD, functional
class, Borg score, quality of life, and pulmonary haemodynamics)
and two pivotal studies, ‘AmbRIESentan in patients with moderate
to severe PAH’, ARIES-1
74 and ARIES-2,
75 that have not yet been
published in full.
The long-term follow-up of patients treated with ambrisentan in
the two pivotal studies and the open-label extension (ARIES-E, n ¼
383) shows that 95% were alive at 1 year and 94% were still receiv-
ing ambrisentan monotherapy, with sustained efﬁcacy for 6MWD,
dyspnoea score, and functional class.
76
Sitaxentan
Sitaxentan sodium, a highly selective ETA-receptor antagonist of
the sulphonamide class of ETRA, has received approval for the
treatment of PAH patients with WHO functional class III symptoms
at an oral dose of 100 mg once daily (European Union, Canada, and
Australia). The FDA has not approved sitaxentan to date, and
another placebo-controlled study with sitaxentan is currently
planned (STRIDE-5) to provide additional data.
ThesafetyandefﬁcacyofsitaxentaninpatientswithPAHhasbeen
clinically tested in the ’sitaxentan to relieve impaired exercise’
(STRIDE) programme,
70 including three randomized, placebo-
controlled pivotal trials (STRIDE-1,
77 STRIDE-2,
78 and STRIDE-4),
two non-controlled studies (Study 211 and STRIDE-6),
79 and
three long-term studies (STRIDE-1X, STRIDE-2X, and STRIDE-3).
Sitaxentan signiﬁcantly improved functional class (STRIDE-1,
STRIDE-2, STRIDE-4), 6MWD (STRIDE-1, STRIDE-2), dyspnoea
score (STRIDE-1), and haemodynamics (Study 211, STRIDE-1).
Improvements in time to clinical worsening could only be demon-
strated in a post hoc meta-analysis using pooled data from the three
pivotal studies.
70
Long-term data are available from a small group of patients,
suggesting that efﬁcacy and safety are maintained for up to
12 months,
80 as well as preliminary data from the extension
studies, with mean exposures of 26 (STRIDE-1X
70) and
36 weeks (STRIDE-2X
81).
Data from subgroup analyses did not exhibit a clinically relevant
treatment effect in patients with PAH associated with CHD.
70 In
contrast, the subgroup of patients with PAH associated with con-
nective tissue disease (CTD) showed an increased 6MWD with
sitaxentan treatment.
82,83
Endothelin-receptor selectivity
and drug efﬁcacy
The most frequent clinical endpoint used to assess drug efﬁcacy in
PAH has been exercise capacity, assessed by the 6MWD, although
its appropriateness as a measure has been debated.
84–86
Moreover, as studies with ETRAs have included different patient
populations, it is difﬁcult to judge, using any measure, whether
ETA selectivity provides a clinically important beneﬁt for patients
with PAH.
6-minute walk distance
Studying the evidence where 6MWD was used as a measure of
efﬁcacy, the placebo-corrected improvements from baseline
to Week 12 (BREATHE-1
62 and ARIES-1
74) or Week 18
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Table 3 Characteristics and main outcomes of pivotal studies for approved endothelin receptor antagonists
Bosentan Sitaxentan Ambrisentan
Study 351
(Channick et al.
61)
BREATHE-1
(Rubin et al.
62)
STRIDE-1
(Barst et al.
77)
STRIDE-2
(Barst et al.
78)
ARIES-1
(Oudiz et al.
74 and PI)
ARIES-2
(Olschewski
108 and PI)
Selectivity Oral ETA/ETB
antagonist
Oral ETA/ETB antagonist Oral highly selective ETA
antagonist
Oral highly selective ETA
antagonist
Oral selective ETA
antagonist
Oral selective ETA
antagonist
Drugs and daily dosages in
the study
Placebo/bosentan
125–250 mg
Placebo/
bosentan 250 mg/
bosentan 500 mg
Placebo/
sitaxentan 100 mg/
sitaxentan 300 mg
Placebo/
sitaxentan 50 mg/
sitaxentan 100 mg/
bosentan
d
Placebo/
ambrisentan 5 mg/
ambrisentan 10 mg
Placebo/
ambrisentan 2.5 mg/
ambrisentan 5 mg
Setting US and EUR US and EUR US (and 1 centre in
Canada)
US and EUR US and EUR US and EUR
Dosing regimen 2 /day 2 /day 1 /day 1 /day 1 /day 1 /day
Study details at inclusion/baseline characteristics
Study duration
post-randomization
(weeks)
12 16 12 18 12 12
Inclusion range for age
(years)
 18  12  16–75 12–78  18  18
Baseline 6 min walk
distance for inclusion (m)
 150 and  500  150 and  450 Not deﬁned (only second
endpoint)
 150 and  450  150 and  450  150 and  450
PAH aetiology IPAH (81%),
PAH-SSc (19%) in
bosentan group
IPAH (71%),
PAH-SSc (23%),
PAH-Lupus (6%)
IPAH (53%),
PAH-CTD (24%),
PAH-CHD (24%)
IPAH (59%),
PAH-CTD (30%),
PAH-CHD (11%)
IPAH (63%),
PAH assoc. with CTD,
HIV, anorexigen (37%)
IPAH (65%),
PAH assoc. with CTD,
HIV, anorexigen (35%)
WHO functional class III (100%) III (90%),
IV (10%)
II (33%),
III (66%),
IV (1%)
II (37%),
III (59%),
IV (4%)
I (3%)
II (32%),
III (58%),
IV (7%)
I and II (46%),
III and IV (54%)
Patient disposition 36 screened,
32 randomized (2:1).
No discontinuations
Screened: n.r.,
213 randomized(1:1:1),
14 discontinued
Screened: n.r.,
178 randomized (1:1:1),
12 discontinued
Screened: n.r.,
247 randomized (1:1:1:1),
31 discontinued
Screened: n.r.,
202 randomized (1:1:1).
discontinuation n.r.
Screened: n.r.,
192 randomized (1:1:1).
discontinuation n.r.
Males:females (%) 19:81 (bosentan) 29:71 (bosentan) 21:79 22:78 n.r. n.r.
Mean age (years) 52 (33–73) (bosentan) 49 (13–80) 46 (17–74) 54 (14–78) n.r. n.r.
Mean 6 min walk distance
at baseline (m)
360 (+86) (bosentan) 330 (+74) 398 (+110) 337 (+80) 341 (+76) 348 (+84)
mPAP (mmHg) 54 (+13) (bosentan) 55 (+16) 54 (+15) 48 (+14) n.r. n.r.
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Table 3 Continued
Bosentan Sitaxentan Ambrisentan
Study 351
(Channick et al.
61)
BREATHE-1
(Rubin et al.
62)
STRIDE-1
(Barst et al.
77)
STRIDE-2
(Barst et al.
78)
ARIES-1
(Oudiz et al.
74 and PI)
ARIES-2
(Olschewski
108 and PI)
Results at study end in the treatment groups
6 min walk distance (m)
a 26/70* 28/27*/47** 213/22**/20** 26.5/17.8/24.9/23.0 27.8/22.8**/43.6*** 210.1/22.2*/49.4***
mRAP (mmHg) 4.9/21.3** n.a. 1/0* n.a. n.a. n.a.
mPAP (mmHg) 5.1/21.6 * n.a. 0 / 23/25*** n.a. n.a. n.a.
Cardiac output (L/min) 20.5/0.5*** (CI) n.a. 0.0/0.3/0.4*** (CI) n.a. n.a. n.a.
PVR (dyn s cm
25) 191/2223*** n.a. 49/2221/2194*** n.a. n.a. n.a.
Median change in peak
VO2 (mL O2/kg/min)
b
n.a. n.a. 0.0/0.5/3.1** n.a. n.a. n.a.
Improvement in Borg
dyspnoea index
1.4/20.2 0.3/20.1/20.6 n.r. 0.2/n.r./0.0/n.r. Ambrisentan yes: details
n.r.
Ambrisentan yes: details
n.r.
Improvement in WHO
functional class (%)
9/43 30/43/41 15/29/30 Sitaxentan 100 mg signif. Ambrisentan yes: details
n.r.
Ambrisentan yes: details
n.r.
Time to clinical
worsening
Sign. improved vs.
placebo
Sign. improved vs. placebo n.r. Sitaxentan 100 mg n.s. (trend
to improv.)
PI: signiﬁcantly delayed
(pooled)
PI: signiﬁcantly delayed
(pooled)
Incidence of clinical
worsening (n)
27/0* 14/5/4 5/0/2 10/6/4/9 Placebo 7 (10%)/
ambrisentan pooled
4 (3%)*
Placebo 13 (22%)/
ambrisentan pooled
8 (6%)*
LFT elevations .3 
ULN (%)
0/6.3 3/4/14 3/0/10 6/5/3/11 3/0/0 2/0/0
Peripheral oedema (%) 5/8
c 5/8
c 17/16/25 8/8/11/15 10 (placebo),
27 (5þ10 mg pooled)
6/8/13
n.a., not applicable (i.e. not done in the study); n.r., not reported; bos, bosentan group only; CI, cardiac index; CHD, congenital heart disease; CTD, connective tissue disease; L, litres; LFT, liver function tests; mPAP, mean pulmonary arterial
pressure; PI, Letairis (ambrisentan) prescribing information (in the US); PVR, pulmonary vascular resistance; ULN, upper limit of normal; VO2, oxygen uptake; WHO, World Health Organization.
aPrimary endpoint in all studies with exception of STRIDE-1.
bPrimary endpoint in STRIDE-1.
cData reported for pooled PAH studies in Tracleerw European Public Assessment Report (EPAR).
dOpen-label bosentan arm at the standard dose, i.e., 62.5 mg orally b.i.d. for 4 weeks, then increasing to the maintenance dose of 125 mg b.i.d.
Statistics vs. placebo: *P , 0.05, **P , 0.01, ***P , 0.001.
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78) were þ35, þ51, and þ31 m for bosentan, ambri-
sentan, and sitaxentan, respectively (Table 3). A direct comparison
is difﬁcult, as BREATHE-1 included only patients in functional class
III and IV while ARIES-1 and STRIDE-2 included  35% of patients
in functional class I and II.
Time to clinical worsening
Signiﬁcant improvements in the time to clinical worsening have
also been reported for all three ETRAs discussed. In
BREATHE-1, both the time to and the incidence of clinical
worsening were signiﬁcantly reduced with bosentan compared
with placebo.
62 In ARIES-1,
74 and ARIES-2,
75 the differences
between ambrisentan and placebo with respect to incidence of
and time to clinical worsening reached statistical signiﬁcance. In a
post hoc meta-analysis pooling 512 patients from STRIDE-1,
STRIDE-2, and STRIDE-4, signiﬁcant improvements in time to
clinical worsening were seen in patients treated with sitaxentan
100 mg daily compared with placebo;
70 this is in contrast to the
individual STRIDE-1
77 and STRIDE-2
78 studies, where statistical
signiﬁcance was not reached.
Haemodynamics
Since ETA and ETB receptors counter-regulate vascular tone,
variations in receptor selectivity could result in different haemo-
dynamic proﬁles.
The haemodynamic changes from baseline to Week 12 for
bosentan and sitaxentan are shown in Table 3. Despite differing
study populations, both drugs equally reduced PVR by an
average of 220 dynes s cm
25 following a 3 month treatment
period; comparable with the decrease of 226+202 dynes s cm
25
reported for ambrisentan.
73 Small differences in favour of less-
selective ETRAs were observed with respect to right atrial
pressure reductions.
Haemodynamic superiority of selective ETA blockade, theoreti-
cally mediated by unblocked ETB receptors, cannot be inferred
from these data. Likewise, non-selective ETRA blockade does
not seem to be associated with clear haemodynamic advantages
when indirectly compared with selective blockade.
Survival
There is no deﬁnitive study proving a survival beneﬁt for any ETRA,
owing to the fact that long-term, placebo-controlled studies are
perceived as ethically unjustiﬁable. Therefore, survival rates for
new PAH therapies are generally compared with historical survival
rates from patients not receiving PAH-speciﬁc drug treatment.
87
For patients enrolled in the two placebo-controlled bosentan
trials and subsequently followed up for a mean of 2.1+
0.5 years, survival estimates were 96 and 89% at 12 and
24 months, compared with a predicted survival of 69 and 57%,
respectively.
63 At the end of 12 and 24 months, 85 and 70% of
patients, respectively, remained on bosentan monotherapy.
Another retrospective analysis of 103 consecutive IPAH patients
treated with ﬁrst-line bosentan therapy reported overall survival
estimates of 92, 89, and 79% at 1, 2, and 3 years, respectively, com-
pared with a predicted survival of 71, 61, and 51% at these time
points
64 (85 and 70% on monotherapy at 12 and 24 months,
respectively). In this group, 44% of patients received additional
intravenous epoprostenol therapy during follow-up.
For ambrisentan, an integrated analysis of 383 PAH patients in
ARIES-l, ARIES-2, or ARIES-E reported an l year survival of
95%.
76 During long-term, open-label treatment (mean, 1.7 years)
of 64 PAH patients treated with ambrisentan, survival in the
IPAH subgroup was 89% (67% on monotherapy) compared with
a predicted survival of 66%.
88,89
Survival data for sitaxentan are available from the STRIDE-2X
programme for 145 patients with PAH treated with sitaxentan
100 mg/day.
81 At 1 year, survival estimates were 96% for the
PAH group and 98% for the subgroup of patients with PAH and
CTD. In both groups, additional PAH therapies had been added
during this period in 13 and 10% of the patients, respectively.
From these data, differential effects on survival with any of the
ETRAs discussed cannot be inferred.
Comparative trials
A unique data set is provided by the STRIDE-2 trial, in which 245
patients were randomized to placebo, sitaxentan (50 or 100 mg
q.d.), or bosentan (62.5 mg b.i.d. for 1 month followed by
125 mg b.i.d.).
78 The bosentan arm was, however, open label and
included only as a comparator arm (events were rater-blinded).
At 18 weeks, both sitaxentan 100 mg and bosentan arms showed
signiﬁcant increases in 6MWD, the primary endpoint. Improve-
ments in functional class (secondary endpoint) were observed
with sitaxentan 100 mg (P ¼ 0.04). Time to clinical worsening did
not improve with either treatment.
After 18 weeks, patients were entered into the extension study
STRIDE-2X where patients who received sitaxentan (100 mg) or
bosentan during STRIDE-2 continued on their respective therapies,
in an open-label fashion. Patients receiving sitaxentan 50 mg daily
during STRIDE-2 had their dosages increased to 100 mg daily,
and the patients on placebo were assigned to sitaxentan (100 mg
daily) or bosentan. Preliminary results of pre-speciﬁed analyses
for patients treated for up to 1 year (bosentan, n ¼ 84; sitaxentan,
n ¼ 145) revealed differences between the treatment arms, with
better outcomes for the sitaxentan-treated patients when com-
pared with bosentan therapy in parameters such as risk of discon-
tinuation of monotherapy (25 vs. 45%, P ¼ 0.003) and abnormal
liver enzyme levels (4 vs. 14%, P ¼ 0.01). However, no signiﬁcant
differences between both treatment regimens were observed for
functional class, 6MWD, or survival.
81 Thus, no clinically meaning-
ful differences between these drugs with respect to
selectivity-related efﬁcacy were observed.
Selectivity and safety
Clinical side effects
Although ETRAs are generally well tolerated, they are associated
with side effects related to their vasodilatory properties including
peripheral oedema, headache, and palpitations. Table 4 provides
an overview on the incidence of those side effects that have the
greatest relevance in everyday clinical care.
ET receptor antagonists in the treatment of PAH 1943Abnormal liver function tests
The most clinically relevant side effects reported with ETRA
therapy are dose-dependent liver function abnormalities. These
present as elevated transaminases and/or bilirubin levels, and are
seen more frequently with the sulfonamide-class ETRAs. Because
these changes are a marker for potentially serious liver injury,
serum aminotransferase levels (and bilirubin if aminotransferase
levels are elevated) must be measured prior to initiation of treat-
ment and then monthly thereafter. It has been reported that
bosentan inhibits the bile salt export pump, which may lead to cho-
lestatic liver injury as a result of the intracellular accumulation of
bile salts, while increasing bile salt-independent bile ﬂow.
90,91
While the incidence of hepatotoxicity in the placebo-controlled
trials was highest with bosentan (Tables 2 and 4), the inclusion cri-
teria and control group characteristics of the studies should be
taken into account. While patients with liver enzyme elevations
.1.5  upper limit of normal (ULN) at baseline were excluded
from ARIES-1, ARIES-2, and STRIDE-2, patients with elevations
up to 3  ULN were included in STRIDE-1 and BREATHE-1. Simi-
larly, the incidence of hepatic aminotransferase elevations .3 
ULN in the control groups varied between 0 and 6% (Table 3).
Consequently, drug surveillance programmes (named TRAcleer
eXcellence Post-Marketing Surveillance Programme, TRAX, for
bosentan, Thelin Outcomes for Patients Surveillance, TOPS, for
sitaxsentan, and VOLibris Tracking, VOLT, for ambrisentan) had/
have to be conducted in the ﬁrst years after introduction for all
ETRAs. In the USA, the marketed drugs (bosentan and ambrisen-
tan) can only be prescribed in the frameworks of special restricted
distribution programmes.
It is a useful ﬁnding that in case of elevated transaminases, a
switch to another ETRA may be an option. The STRIDE-6
study
79 aimed to explore the potential use of sitaxentan in PAH
patients who previously discontinued bosentan treatment (13
patients owing to ‘safety issues’, 12 patients with aminotransferase
elevations, and one patient with rash). Among the 12 patients with
liver enzyme elevations on bosentan treatment, only one individual
re-developed this side effect during 12 weeks of sitaxentan
therapy. An open-label study of ambrisentan evaluated the hypoth-
esis that patients previously discontinued from bosentan (86%),
sitaxentan (6%), or both (8%) because of elevations in hepatic
aminotransferases can be successfully treated with ambrisentan
without recurrence of hepatotoxicity. None of these 36 patients
developed recurrent liver transaminase elevations during the
initial 12 week observation period.
92 In conclusion, among the
various ETRAs currently available for the treatment of patients
with PAH, receptor selectivity itself does not appear to be
related to the incidence of hepatotoxicity. It is likely that chemical
properties of the drugs, the pharmacokinetics or drug–drug inter-
actions, or patient characteristics, may inﬂuence the incidence and
severity of the side effects rather than differences in ET-receptor
selectivity.
Decreased haemoglobin
Owing to an as yet incompletely identiﬁed mechanism, potentially
related to vasodilatation and subsequent ﬂuid shift producing
haemodilution, all ETRAs are associated with a usually modest,
dose-dependent, and partially transient reduction in haemoglobin
levels. Decreases in haemoglobin were not related to haemolysis,
bone marrow depression, or risk of bleeding. They occur in
about 5–7% of patients, irrespective of the ETRA used. Haemo-
globin (and haematocrit) reductions are likely to be a dose-
dependent class effect of the ETRAs that may not be attributable
to receptor selectivity.
For all three agents, these symptoms typically do not require
discontinuation of therapy or dose adjustment and are usually
not dose dependent (up to the approved doses). The occurrence,
frequency, and severity of these side effects appear not to be
related to the degree of selectivity for the ETA receptor.
...............................................................................................................................................................................
Table 4 Frequent side effects of the three endothelin receptor antagonists in pulmonary arterial hypertension patients
according to labelling
Side effect Sitaxentan Bosentan Ambrisentan
ALT/AST
elevations
.3  ULN: 7% for sitaxentan 100 mg/day
treated patients (n ¼ 887) vs. 5% of
PBO-treated patients (n ¼ 155).
.3  ULN: eight integrated PBO-controlled studies (six
other than PAH): 11.2% of the bosentan vs. 1.8% of the
PBO-treated patients.
.3  ULN: 0.8% for
ambrisentan vs. 0.2%
PBO
.5  ULN: 4% (36/887) for sitaxentan
100 mg/day vs. 0.6% in the PBO group
(1/155).
In PAH: 11.6% for bosentan 125 mg b.i.d., and 14.3% for
bosentan 250 mg twice daily. .8  ULN: 2.1% for
bosentan 125 mg b.i.d. vs. 7.1% for 250 mg twice daily.
.8  ULN 0.2% for
ambrisentan vs. 0% for
PBO.
Peripheral
oedema
9% PBO-controlled studies 4.7 vs. 1.4% PBO
BREATHE-5 study: 18.9 vs. 5.9% PBO
17% (PBO-adjusted 6%)
BREATHE-4 study 31% (no PBO comparison)
RAPIDS-1, -2: 14 vs. 5% PBO
Headache 15% PBO-controlled studies 15.8 vs. 12.8% PBO
BREATHE-5 study: 13.5 vs. 11.8% PBO
15% (PBO-adjusted 1%)
BREATHE-4 study 19% (no PBO comparison)
Decreased
haemoglobin
7% (PBO-adjusted 4%) 5.6 (PBO-adjusted 3.0%) 7% (PBO-adjusted 3%)
Source: Product information (Summary of Product Characteristics, SmPC) of Tracleer, Thelin, and Letairis. ALT, alanine aminotransferases;AST, aspartateaminotransferases;ULN,
upper limit of normal; PBO, placebo.
C.F. Opitz et al. 1944Peripheral oedema
There has been speculation as to whether peripheral oedema
occurs more frequently as a drug-speciﬁc, ETB-mediated side
effect. However, the incidences of leg oedema in the pivotal
ETRA studies (Table 4) suggest that the incidence is related to
patient characteristics (as can be derived from the large variance
in the placebo groups), but do not suggest a signiﬁcant drug-related
effect. Notably, a warning label has been issued by the FDA for
ambrisentan based on post-marketing reports of ﬂuid retention
occurring within weeks after starting ambrisentan.
71
Selectivity and PAH associated
with connective tissue disease
Of the wide spectrum of diseases encompassed by the term ‘pul-
monary hypertension’, PAH with associated CTD (PAH-CTD) is a
disease for which patients have a particularly poor prognosis.
Importantly, this subgroup has been included in several trials eval-
uating ETRAs; however, the clinical relevance of ET-receptor
selectivity in this patient group has not been speciﬁcally explored.
The BREATHE-1 trial included 47 patients with systemic scler-
osis (22%).
62 In contrast to patients with IPAH, bosentan did not
signiﬁcantly increase 6MWD. However, the decline in walking dis-
tance of 40 m at 16 weeks in the systemic sclerosis placebo group
(n ¼ 14) was prevented by bosentan (þ3m ,n ¼ 33).
For ambrisentan, comparable efﬁcacy with respect to functional
capacity, measured as 6MWD, was described for 19 patients (30%)
with PAH associated with collagen vascular disease, when com-
pared to patients with idiopathic PAH.
73
A post hoc analysis of 42 patients with PAH-CTD enrolled in the
STRIDE-1 study
83 showed that during the 12 week placebo-
controlled phase, sitaxentan (pooled 100 and 300 mg groups)
increased the placebo-subtracted 6MWD by 58 m (P ¼ 0.027),
improved haemodynamics, as well as certain domains within the
quality-of-life assessment. Notably, in contrast to the bosentan
data, sitaxentan not only prevented deterioration of exercise
capacity but also signiﬁcantly improved 6MWD by 20m (P ¼ 0.037),
compared with baseline. In another post hoc meta-analysis
pooling 512 patients from STRIDE-1, STRIDE-2, and STRIDE-4, a
subgroup of 129 patients with PAH-CTD was analysed. Within
this subgroup, 39 patients treated with sitaxentan 100 mg daily
showed a signiﬁcantly improved 6MWD by 38 m (P ¼ 0.0419),
compared with placebo.
70 This effect was not seen with sitaxentan
50 or 300 mg daily in this PAH subgroup.
Long-term outcomes in PAH-CTD
Retrospective analyses have been published examining the long-
term effects of ETRAs in patients with PAH-CTD. In two random-
ized, controlled studies investigating bosentan in PAH,
61,62 66
patients with PAH-CTD were randomized to receive either bosen-
tan (n ¼ 44) or placebo (n ¼ 22). Forty-four patients on bosentan
were stable in 6MWD at study end, while the placebo patients
deteriorated; the placebo-subtracted difference was 22 m (non-
signiﬁcant). Subsequently, in an open-label, long-term extension
study (1.6+0.9 years), survival rate in the 64 patients receiving
bosentan was 86% after 1 year and 73% after 2 years.
93 These
outcome data are comparable with the 81 and 71% survival
rates at 1 and 3 years, respectively, seen among 45 patients
with PAH associated with scleroderma, treated with bosentan
(mono- or combination therapy), as detailed in the Royal Free
Hospital registry. These ﬁndings compare favourably to the
68 and 47% survival rates at 1 and 2 year, respectively, in a
historical cohort of 47 patients in the same institution treated
with conventional therapy.
94
Within the STRIDE-2X study, 52 patients with PAH-CTD
(scleroderma, n ¼ 38; overlap syndrome, n ¼ 9; lupus, n ¼ 5)
were included. According to a preliminary report,
82 for this
subgroup, time to discontinuation owing to adverse events or
elevated hepatic aminotransferase, time to clinical worsening,
and 1 year survival were all improved with sitaxentan therapy
compared with placebo. In the STRIDE-1X study, at the end of
the blinded extension phase, following mean treatment duration
of 26 weeks, signiﬁcantly more patients were in functional class I
or II with sitaxentan, compared with baseline.
70
Taken together, these data document short- and long-term clini-
cal efﬁcacy for ETRAs in the subgroup of patients with PAH-CTD.
When comparing these post hoc analyses, an advantage of selective
ETA blockade appears possible, since some of the efﬁcacy end-
points reached statistical signiﬁcance only with sitaxentan treat-
ment. Differential effects on survival with these ETRAs cannot
be evaluated from these data.
Drug metabolism, drug
interactions, and combination
therapy
Bosentan, ambrisentan, and sitaxentan have divergent pharmaco-
logical and pharmacokinetic characteristics, resulting in clinically
important differences with respect to drug metabolism, drug inter-
actions, and their potential for use in combination therapy
(Table 2). Of interest are the interactions of bosentan with silde-
naﬁl, a frequently used combination therapy, where sildenaﬁl
plasma levels are reduced by about 50% while bosentan concen-
trations rise by approximately 50%.
95,96 Theoretically, sub-
therapeutic sildenaﬁl levels as well as increased bosentan-related
liver toxicity may result. However, in clinical practice, this combi-
nation is well tolerated and appears to be effective.
97 No such
interaction with sildenaﬁl has been described for ambrisentan or
sitaxentan.
Other important co-medications in patients with PAH are
vitamin-K antagonists. Bosentan and sitaxentan have different
effects on the doses of oral anticoagulants (vitamin-K antagonists):
bosentan partially induces the cytochrome P450 system, thereby
increasing warfarin metabolism and the required dose.
98,104 In
contrast, sitaxentan inhibits the liver isoenzyme CYP2C9. Thus,
combining sitaxentan and warfarin in healthy volunteers can
lead to a 2.4-fold increase in exposure to warfarin, therefore,
requiring a substantial reduction in dose (80%) at initiation of
therapy to avoid bleeding complications.
99 No such interaction
occurs with ambrisentan; however, according to the labelling,
the drug interaction potential of ambrisentan ‘has not been well
characterized’.
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ET receptor antagonists in the treatment of PAH 1945In summary, most of these characteristics are related to the
class of drug and differences in metabolism instead of reﬂecting
differences in ET-receptor selectivity.
Conclusions
Together, these data, derived mainly from a series of randomized,
controlled trials and their open-label extensions, conﬁrm that ET
antagonism is an effective and generally well-tolerated treatment
option for patients with symptomatic PAH. They represent a
major advance within the available therapeutic armamentarium
for this severely compromised patient population.
Considering the entire group of PAH patients who have been
prospectively studied in these trials, a clinically meaningful differ-
ence between the three approved ETRAs with respect to their
ET-receptor selectivity could not be demonstrated to date. There-
fore, in clinical practice, other features are likely to be of greater
relevance when considering treatment, such as the potential for
serious drug–drug interactions, convenience of dosing schedule,
or rates of limiting side effects. These characteristics bear more
relation to the chemical or pharmacological properties of the
drug than to receptor selectivity itself.
Another important limitation of the data discussed in this paper
relates to the design of the studies. As mentioned earlier, ET-1
creates short-term effects, mainly vasoconstriction, as well as
medium and long-term sequelae such as proliferation, inﬂam-
mation, and ﬁbrosis. Most of the studies discussed in this paper
investigated the effects of pharmacological interventions over the
periods of 12–16 weeks, thereby assessing only the short-term
vasodilator potential of the drug under study.
100 From this per-
spective, the agents examined all resulted in a small, though signiﬁ-
cant change in exercise capacity over 12–16 weeks, irrespective of
the drug used.
86 Considering these limitations, much longer
follow-up periods and probably other endpoints might be necess-
ary to detect clinically important differences related to receptor
selectivity when comparing different ETRAs. Until the results
from such long-term trials become available, other strategies can
be used to acquire data on the effects of different ETRAs in the
treatment of patients with PAH. As one of these projects, the
‘Comparison of Endothelin Receptor Antagonist therapy in
routine care’ (CompERA, http://compera.org/) has recently been
initiated in the European Union. This prospective large-scale
register documents safety and efﬁcacy parameters in consecutive
pulmonary hypertension patients treated with any of the approved
ETRAs (as mono- or combination therapy). These data should
contribute to the optimization of the current ETRA-based drug
therapy and provide further insight into selectivity-related differ-
ences among the currently available drugs.
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Supplementary material is available at European Heart Journal
online.
Conﬂict of interest: none declared.
Funding
Funding to pay the Open Access publication charges for this article
was provided by Christian Opitz and David Pittrow.
References
1. Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 2004;351:
1655–1665.
2. Galie N, Torbicki A, Barst R, Dartevelle P, Haworth S, Higenbottam T,
Olschewski H, Peacock A, Pietra G, Rubin LJ, Simonneau G, Priori SG,
Garcia MA, Blanc JJ, Budaj A, Cowie M, Dean V, Deckers J, Burgos EF,
Lekakis J, Lindahl B, Mazzotta G, McGregor K, Morais J, Oto A, Smiseth OA,
Barbera JA, Gibbs S, Hoeper M, Humbert M, Naeije R, Pepke-Zaba J. Guidelines
on diagnosis and treatment of pulmonary arterial hypertension. The Task Force
on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the
European Society of Cardiology. Eur Heart J 2004;25:2243–2278.
3. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hyperten-
sion. N Engl J Med 2004;351:1425–1436.
4. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y,
Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular
endothelial cells. Nature 1988;332:411–415.
5. Ito H, Hirata Y, Hiroe M, Tsujino M, Adachi S, Takamoto T, Nitta M, Taniguchi K,
Marumo F. Endothelin-1 induces hypertrophy with enhanced expression of
muscle-speciﬁc genes in cultured neonatal rat cardiomyocytes. Circ Res 1991;
69:209–215.
6. Kahaleh MB. Endothelin, an endothelial-dependent vasoconstrictor in sclero-
derma. Enhanced production and proﬁbrotic action. Arthritis Rheum 1991;34:
978–983.
7. Xu SW, Denton CP, Dashwood MR, Abraham DJ, Black CM. Endothelin-1
regulation of intercellular adhesion molecule-1 expression in normal and
sclerodermal ﬁbroblasts. J Cardiovasc Pharmacol 1998;31(Suppl. 1):S545–S547.
8. Filep JG, Fournier A, Foldes-Filep E. Acute pro-inﬂammatory actions of
endothelin-1 in the guinea-pig lung: involvement of ETA and ETB receptors.
Br J Pharmacol 1995;115:227–236.
9. Belloni AS, Rossi GP, Andreis PG, Neri G, Albertin G, Pessina AC,
Nussdorfer GG. Endothelin adrenocortical secretagogue effect is mediated by
the B receptor in rats. Hypertension 1996;27:1153–1159.
10. Schiffrin EL, Touyz RM. Vascular biology of endothelin. J Cardiovasc Pharmacol
1998;32(Suppl. 3):S2–S13.
11. Nootens M, Kaufmann E, Rector T, Toher C, Judd D, Francis GS, Rich S. Neuro-
hormonal activation in patients with right ventricular failure from pulmonary
hypertension: relation to hemodynamic variables and endothelin levels. JA m
Coll Cardiol 1995;26:1581–1585.
12. Rubens C, Ewert R, Halank M, Wensel R, Orzechowski HD, Schultheiss HP,
Hoeffken G. Big endothelin-1 and endothelin-1 plasma levels are correlated with
the severity of primary pulmonary hypertension. Chest 2001;120:1562–1569.
13. Galie N, Grigioni F, Bacchi-Reggiani L. Relation of endothelin-1 to survival in
patients with primary pulmonary hypertension [abstract 273]. Eur J Clin Invest
1996;26:A48.
14. Gregan B, Schaefer M, Rosenthal W, Oksche A. Fluorescence resonance energy
transfer analysis reveals the existence of endothelin-a and endothelin-b receptor
homodimers. J Cardiovasc Pharmacol 2004;44:S30–S33.
15. Sauvageau S, Thorin E, Caron A, Dupuis J. Endothelin-1-induced pulmonary
vasoreactivity is regulated by ET(A) and ET(B) receptor interactions. J Vasc
Res 2007;44:375–381.
16. Clozel M, Gray GA. Are there different ETB receptors mediating constriction
and relaxation? J Cardiovasc Pharmacol 1995;26(Suppl. 3):S262–S264.
17. Ohlstein EH, Arleth A, Bryan H, Elliott JD, Sung CP. The selective endothelin
ETA receptor antagonist BQ123 antagonizes endothelin-1-mediated mitogen-
esis. Eur J Pharmacol 1992;225:347–350.
18. Alberts GF, Peiﬂey KA, Johns A, Kleha JF, Winkles JA. Constitutive endothelin-1
overexpression promotes smooth muscle cell proliferation via an external
autocrine loop. J Biol Chem 1994;269:10112–10118.
19. Andrawis NS, Wang E, Abernethy DR. Endothelin-1 induces an increase in
total protein synthesis and expression of the smooth muscle alpha-actin gene
in vascular smooth muscle cells. Life Sci 1996;59:523–528.
20. Kernochan LE, Tran BN, Tangkijvanich P, Melton AC, Tam SP, Yee HF Jr.
Endothelin-1 stimulates human colonic myoﬁbroblast contraction and migration.
Gut 2002;50:65–70.
21. Shichiri M, Kato H, Marumo F, Hirata Y. Endothelin-1 as an autocrine/paracrine
apoptosis survival factor for endothelial cells. Hypertension 1997;30:1198–1203.
22. Dupuis J, Cernacek P, Tardif JC, Stewart DJ, Gosselin G, Dyrda I, Bonan R,
Crepeau J. Reduced pulmonary clearance of endothelin-1 in pulmonary
hypertension. Am Heart J 1998;135:614–620.
C.F. Opitz et al. 194623. Naomi S, Iwaoka T, Disashi T, Inoue J, Kanesaka Y, Tokunaga H, Tomita K.
Endothelin-1 inhibits endothelin-converting enzyme-1 expression in cultured
rat pulmonary endothelial cells. Circulation 1998;97:234–236.
24. Davie N, Haleen SJ, Upton PD, Polak JM, Yacoub MH, Morrell NW, Wharton J.
ET(A) and ET(B) receptors modulate the proliferation of human pulmonary
artery smooth muscle cells. Am J Respir Crit Care Med 2002;165:398–405.
25. Masaki T. Possible role of endothelin in endothelial regulation of vascular tone.
Annu Rev Pharmacol Toxicol 1995;35:235–255.
26. Dong F, Zhang X, Wold LE, Ren Q, Zhang Z, Ren J. Endothelin-1 enhances
oxidative stress, cell proliferation and reduces apoptosis in human umbilical
vein endothelial cells: role of ETB receptor, NADPH oxidase and caveolin-1.
Br J Pharmacol 2005;145:323–333.
27. Bagnall A, Webb D. Are selective endothelin A receptor antagonists better than
mixed antagonists? J Cardiovasc Pharmacol 2001;38(Suppl. 2):S43–S46.
28. Clozel M. Effects of bosentan on cellular processes involved in pulmonary
arterial hypertension: do they explain the long-term beneﬁt? Ann Med 2003;
35:605–613.
29. Langleben D, Dupuis J, Langleben I, Hirsch AM, Baron M, Senecal JL,
Giovinazzo M. Etiology-speciﬁc endothelin-1 clearance in human precapillary
pulmonary hypertension. Chest 2006;129:689–695.
30. Goddard J, Johnston NR, Hand MF, Cumming AD, Rabelink TJ, Rankin AJ,
Webb DJ. Endothelin-A receptor antagonism reduces blood pressure and
increases renal blood ﬂow in hypertensive patients with chronic renal failure:
a comparison of selective and combined endothelin receptor blockade.
Circulation 2004;109:1186–1193.
31. Dupuis J. Endothelin receptor antagonists and their developing role in
cardiovascular therapeutics. Can J Cardiol 2000;16:903–910.
32. Bolli MH, Marfurt J, Grisostomi C, Boss C, Binkert C, Hess P, Treiber A,
Thorin E, Morrison K, Buchmann S, Bur D, Ramuz H, Clozel M, Fischli W,
Weller T. Novel benzo[1,4]diazepin-2-one derivatives as endothelin receptor
antagonists. J Med Chem 2004;47:2776–2795.
33. Greene S, Nunley K, Weber S, Minobe W, Bristow MR. ETA vs. ETB receptor
selectivity of endothelin-1 receptor antagonists. J Am Coll Cardiol 2006;47:307A.
34. Givertz MM, Colucci WS, LeJemtel TH, Gottlieb SS, Hare JM, Slawsky MT,
Leier CV, Loh E, Nicklas JM, Lewis BE. Acute endothelin A receptor blockade
causes selective pulmonary vasodilation in patients with chronic heart failure.
Circulation 2000;101:2922–2927.
35. Food and Drug Administration/CDER LETAIRISw (ambrisentan tables). Clinical
Pharmacology. Biopharmaceutics Review 2007;3:98–99. http://www.fda.gov/cder/
foi/nda/2007/022081s000_ClinPharmR_P3.pdf (28 May 2008).
36. Opitz CF, Ewert R. Dual ET(A)/ET(B) vs. selective ET(A) endothelin receptor
antagonism in patients with pulmonary hypertension. Eur J Clin Invest 2006;
36(Suppl. 3):1–9.
37. Love MP, Ferro CJ, Haynes WG, Plumpton C, Davenport AP, Webb DJ,
McMurray JJ. Endothelin receptor antagonism in patients with chronic heart
failure. Cardiovasc Res 2000;47:166–172.
38. Verhaar MC, Strachan FE, Newby DE, Cruden NL, Koomans HA, Rabelink TJ,
Webb DJ. Endothelin-A receptor antagonist-mediated vasodilatation is attenu-
ated by inhibition of nitric oxide synthesis and by endothelin-B receptor block-
ade. Circulation 1998;97:752–756.
39. Chen SJ, Chen YF, Meng QC, Durand J, Dicarlo VS, Oparil S. Endothelin-
receptor antagonist bosentan prevents and reverses hypoxic pulmonary
hypertension in rats. J Appl Physiol 1995;79:2122–2131.
40. Kim H, Yung GL, Marsh JJ, Konopka RG, Pedersen CA, Chiles PG, Morris TA,
Channick RN. Endothelin mediates pulmonary vascular remodelling in a
canine model of chronic embolic pulmonary hypertension. Eur Respir J 2000;
15:640–648.
41. Chen SJ, Chen YF, Opgenorth TJ, Wessale JL, Meng QC, Durand J, DiCarlo VS,
Oparil S. The orally active nonpeptide endothelin A-receptor antagonist
A-127722 prevents and reverses hypoxia-induced pulmonary hypertension
and pulmonary vascular remodeling in Sprague-Dawley rats. J Cardiovasc
Pharmacol 1997;29:713–725.
42. DiCarlo VS, Chen SJ, Meng QC, Durand J, Yano M, Chen YF, Oparil S.
ETA-receptor antagonist prevents and reverses chronic hypoxia-induced
pulmonary hypertension in rat. Am J Physiol 1995;269:L690–L697.
43. Tilton RG, Munsch CL, Sherwood SJ, Chen SJ, Chen YF, Wu C, Block N,
Dixon RA, Brock TA. Attenuation of pulmonary vascular hypertension and
cardiac hypertrophy with sitaxsentan sodium, an orally active ET(A) receptor
antagonist. Pulm Pharmacol Ther 2000;13:87–97.
44. Clozel M, Salloukh H. Role of endothelin in ﬁbrosis and anti-ﬁbrotic potential of
bosentan. Ann Med 2005;37:2–12.
45. Hocher B, Schwarz A, Fagan KA, Thone-Reineke C, El-Hag K, Kusserow H,
Elitok S, Bauer C, Neumayer HH, Rodman DM, Theuring F. Pulmonary ﬁbrosis
and chronic lung inﬂammation in ET-1 transgenic mice. Am J Respir Cell Mol Biol
2000;23:19–26.
46. Coghlan JG, Mukerjee D. The heart and pulmonary vasculature in scleroderma:
clinical features and pathobiology. Curr Opin Rheumatol 2001;13:495–499.
47. Forbes JM, Hewitson TD, Becker GJ, Jones CL. Simultaneous blockade of
endothelin A and B receptors in ischemic acute renal failure is detrimental to
long-term kidney function. Kidney International 2001;59:1333–1341.
48. Yoshida J, Yamamoto K, Mano T, Sakata Y, Nishikawa N, Miwa T, Hori M,
Masuyama T. Angiotensin II type 1 and endothelin type A receptor antagonists
modulate the extracellular matrix regulatory system differently in diastolic heart
failure. J Hypertens 2003;21:437–444.
49. Ammarguellat F, Larouche I, Schiffrin EL. Myocardial ﬁbrosis in DOCA-salt
hypertensive rats: effect of endothelin ET(A) receptor antagonism. Circulation
2001;103:319–324.
50. Ergul A, Portik-Dobos V, Giulumian AD, Molero MM, Fuchs LC. Stress upregu-
lates arterial matrix metalloproteinase expression and activity via endothelin A
receptor activation. Am J Physiol 2003;285:H2225–H2232.
51. Seccia TM, Belloni AS, Kreutz R, Paul M, Nussdorfer GG, Pessina AC, Rossi GP.
Cardiac ﬁbrosis occurs early and involves endothelin and AT-1 receptors in
hypertension due to endogenous angiotensin II. J Am Coll Cardiol 2003;41:
666–673.
52. Boffa JJ, Tharaux PL, Dussaule JC, Chatziantoniou C. Regression of renal vascular
ﬁbrosis by endothelin receptor antagonism. Hypertension 2001;37:490–496.
53. Park SH, Saleh D, Giaid A, Michel RP. Increased endothelin-1 in
bleomycin-induced pulmonary ﬁbrosis and the effect of an endothelin receptor
antagonist. Am J Respir Crit Care Med 1997;156:600–608.
54. Shi-Wen X, Denton CP, Dashwood MR, Holmes AM, Bou-Gharios G,
Pearson JD, Black CM, Abraham DJ. Fibroblast matrix gene expression and con-
nective tissue remodeling: role of endothelin-1. J Invest Dermatol 2001;116:
417–425.
55. Shi-Wen X, Chen Y, Denton CP, Eastwood M, Renzoni EA, Bou-Gharios G,
Pearson JD, Dashwood M, du Bois RM, Black CM, Leask A, Abraham DJ.
Endothelin-1 promotes myoﬁbroblast induction through the ETA receptor via
a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for
the enhanced contractile phenotype of ﬁbrotic ﬁbroblasts. Mol Biol Cell 2004;
15:2707–2719.
56. Nakamura T, Ebihara I, Tomino Y, Koide H. Effect of a speciﬁc endothelin A
receptor antagonist on murine lupus nephritis. Kidney Int 1995;47:481–489.
57. Dawes KE, Cambrey AD, Campa JS, Bishop JE, McAnulty RJ, Peacock AJ,
Laurent GJ. Changes in collagen metabolism in response to endothelin-1: evi-
dence for ﬁbroblast heterogeneity. Int J Biochem Cell Biol 1996;28:229–238.
58. Wang X, Douglas SA, Louden C, Vickery-Clark LM, Feuerstein GZ, Ohlstein EH.
Expression of endothelin-1, endothelin-3, endothelin-converting enzyme-1, and
endothelin-A and endothelin-B receptor mRNA after angioplasty-induced
neointimal formation in the rat. Circ Res 1996;78:322–328.
59. Mallat A, Fouassier L, Preaux AM, Gal CS, Raufaste D, Rosenbaum J,
Dhumeaux D, Jouneaux C, Mavier P, Lotersztajn S. Growth inhibitory properties
of endothelin-1 in human hepatic myoﬁbroblastic Ito cells. An endothelin B
receptor-mediated pathway. J Clin Invest 1995;96:42–49.
60. Abraham DJ, Vancheeswaran R, Dashwood MR, Rajkumar VS, Pantelides P,
Xu SW, du Bois RM, Black CM. Increased levels of endothelin-1 and differential
endothelin type A and B receptor expression in scleroderma-associated ﬁbrotic
lung disease. Am J Pathol 1997;151:831–841.
61. Channick R, Badesch DB, Tapson VF, Simonneau G, Robbins I, Frost A, Roux S,
Rainisio M, Bodin F, Rubin LJ. Effects of the dual endothelin receptor antagonist
bosentan in patients with pulmonary hypertension: a placebo-controlled study.
J Heart Lung Transplant 2001;20:262–263.
62. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A,
Roux S, Leconte I, Landzberg M, Simonneau G. Bosentan therapy for pulmonary
arterial hypertension. N Engl J Med 2002;346:896–903.
63. McLaughlin VV, Sitbon O, Badesch DB, Barst RJ, Black C, Galie N, Rainisio M,
Simonneau G, Rubin LJ. Survival with ﬁrst-line bosentan in patients with
primary pulmonary hypertension. Eur Respir J 2005;25:244–249.
64. Provencher S, Sitbon O, Humbert M, Cabrol S, Jais X, Simonneau G. Long-term
outcome with ﬁrst-line bosentan therapy in idiopathic pulmonary arterial hyper-
tension. Eur Heart J 2006;27:589–595.
65. Barst RJ, Ivy D, Dingemanse J, Widlitz A, Schmitt K, Doran A, Bingaman D,
Nguyen N, Gaitonde M, van Giersbergen PL. Pharmacokinetics, safety, and efﬁ-
cacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin
Pharmacol Ther 2003;73:372–382.
66. Sitbon O, Gressin V, Speich R, Macdonald PS, Opravil M, Cooper DA, Fourme T,
Humbert M, Delfraissy JF, Simonneau G. Bosentan for the treatment of human
immunodeﬁciency virus-associated pulmonary arterial hypertension. Am J Respir
Crit Care Med 2004;170:1212–1217.
67. Galie N, Beghetti M, Gatzoulis MA, Granton J, Berger RM, Lauer A, Chiossi E,
Landzberg M. Bosentan therapy in patients with Eisenmenger syndrome: a
ET receptor antagonists in the treatment of PAH 1947multicenter, double-blind, randomized, placebo-controlled study. Circulation
2006;114:48–54.
68. Hoeper MM, Seyfarth HJ, Hoeffken G, Wirtz H, Spiekerkoetter E, Pletz MW,
Welte T, Halank M. Experience with inhaled iloprost and bosentan in portopul-
monary hypertension. Eur Respir J 2007;30:1096–1102.
69. Galie N. The endothelin antagonist trial in mildly symptomatic PAH patients
(EARLY) (Abstract 1011). Eur Heart J 2007;28:140.
70. Barst RJ. Sitaxsentan: a selective endothelin-A receptor antagonist, for the
treatment of pulmonary arterial hypertension. Expert Opin Pharmacother 2007;
8:95–109.
71. Gilead Pharmaceuticals. Letairis(R) (Ambrisentan) full prescribing information.
2007. http://www.gilead.com/pdf/letairis_pi.pdf (27 May 2008).
72. EMEA. Summary of opinion. Volibris (ambrisentan). 2008. http://www.emea.
europa.eu/pdfs/human/opinion/Volibris_3142508en%20.pdf (22 March 2008).
73. Galie N, Badesch D, Oudiz R, Simonneau G, McGoon MD, Keogh AM, Frost AE,
Zwicke D, Naeije R, Shapiro S, Olschewski H, Rubin LJ. Ambrisentan therapy
for pulmonary arterial hypertension. J Am Coll Cardiol 2005;46:529–535.
74. Oudiz R, Torres F, Frost A, Badesch D, Olschewski H, Galie N, McGoon MD,
McLaughin VV, Rubin L. ARIES-1: a placebo-controlled, efﬁcacy and safety
study of ambrisentan in patients with pulmonary arterial hypertension. Chest
2006;130:121S.
75. Oudiz R, Olschewski H, Galie N, Frost A, Badesch D, McGoon MD,
McLaughin VV, Rubin L. Ambrisentan improves exercise capacity and time to
clinical worsening in patients with pulmonary arterial hypertension: results
of the ARIES-2 study. International Conference of the American Thoracic Society,
19–24 May 2006. San Diego, CA: American Thoracic Society; 2006.
76. Oudiz R, Badesch D, Rubin L. ARIES-E: Long-term safety and efﬁcacy of
ambrisentan in pulmonary arterial hypertension. Chest 2007;132:474a.
77. Barst RJ, Langleben D, Frost A, Horn EM, Oudiz R, Shapiro S, McLaughlin V,
Hill N, Tapson VF, Robbins IM, Zwicke D, Duncan B, Dixon RA, Frumkin LR.
Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care
Med 2004;169:441–447.
78. Barst RJ, Langleben D, Badesch D, Frost A, Lawrence EC, Shapiro S, Naeije R,
Galie N. Treatment of pulmonary arterial hypertension with the selective
endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 2006;47:
2049–2056.
79. Benza RL, Mehta S, Keogh A, Lawrence EC, Oudiz RJ, Barst RJ. Sitaxsentan treat-
ment for patients with pulmonary arterial hypertension discontinuing bosentan.
J Heart Lung Transplant 2007;26:63–69.
80. Langleben D, Hirsch AM, Shalit E, Lesenko L, Barst RJ. Sustained symptomatic,
functional, and hemodynamic beneﬁt with the selective endothelin-A receptor
antagonist, sitaxsentan, in patients with pulmonary arterial hypertension: a
1-year follow-up study. Chest 2004;126:1377–1381.
81. Benza RL, Frost A, Girgis R, Langleben D, Lawrence EC, Naeije R. Chronic
treatment of pulmonary arterial hypertension (PAH) with sitaxentan and
bosentan [abstract]. Proc Am Thorac Soc 2006;3:A729.
82. Highland KB, Strange C, Girgis R, Black C. Comparison of sitaxentan and
bosentan in PAH-CTD. Ann Rheum Dis 2006;65(Suppl. II):393.
83. Girgis RE, Frost AE, Hill NS, Horn EM, Langleben D, Mc Laughlin VV, Oudiz RJ,
Robbins IM, Seibold JR, Shapiro S, Tapson VF, Barst RJ. Selective endothelin A
receptor antagonism with sitaxsentan for pulmonary arterial hypertension
associated with connective tissue disease. Ann Rheum Dis 2007;66:1467–1472.
84. Hoeper MM, Oudiz RJ, Peacock A, Tapson VF, Haworth SG, Frost AE,
Torbicki A. End points and clinical trial designs in pulmonary arterial hyperten-
sion: clinical and regulatory perspectives. J Am Coll Cardiol 2004;43(Suppl. 12S):
48S–55S.
85. Frost AE, Langleben D, Oudiz R, Hill N, Horn E, McLaughlin V, Robbins IM,
Shapiro S, Tapson VF, Zwicke D, DeMarco T, Schilz R, Rubenﬁre M, Barst RJ.
The 6-min walk test (6MW) as an efﬁcacy endpoint in pulmonary arterial
hypertension clinical trials: demonstration of a ceiling effect. Vascul Pharmacol
2005;43:36–39.
86. Rich S. The value of approved therapies for pulmonary arterial hypertension.
Am Heart J 2007;153:889–890.
87. D’Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM,
Fishman AP, Goldring RM, Groves BM, Kernis JT et al. Survival in patients
with primary pulmonary hypertension. Results from a national prospective
registry. Ann Intern Med 1991;115:343–349.
88. Olschewski H. Long-term safety and tolerance of ambrisentan in patients with
pulmonary arterial hypertension. (Abstract). Eur Respir J 2005;26(Suppl. 49):
205s.
89. Barst RJ. A review of pulmonary arterial hypertension: role of ambrisentan. Vasc
Health Risk Manag 2007;3:11–22.
90. Fattinger K, Funk C, Pantze M, Weber C, Reichen J, Stieger B, Meier PJ. The
endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a
potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther 2001;
69:223–231.
91. Mano Y, Usui T, Kamimura H. Effects of bosentan, an endothelin receptor
antagonist, on bile salt export pump and multidrug resistance-associated
protein 2. Biopharm Drug Dispos 2007;28:13–18.
92. McGoon M, Frost A, Oudiz R, Badesch D, Galie N, Olschewski H,
McLaughin VV, Rubin L. Ambrisentan rescue therapy in patients with pulmonary
arterial hypertension who discontinued bosentan or sitaxentan due to liver
function abnormalities. Chest 2006;254S.
93. Denton CP, Humbert M, Rubin L, Black CM. Bosentan treatment for pulmonary
arterial hypertension related to connective tissue disease: a subgroup analysis of
the pivotal clinical trials and their open-label extensions. Ann Rheum Dis 2006;65:
1336–1340.
94. Williams MH, Das C, Handler CE, Akram MR, Davar J, Denton CP, Smith CJ,
Black CM, Coghlan JG. Systemic sclerosis associated pulmonary hypertension:
improved survival in the current era. Heart 2006;92:926–932.
95. Paul GA, Gibbs JS, Boobis AR, Abbas A, Wilkins MR. Bosentan decreases the
plasma concentration of sildenaﬁl when coprescribed in pulmonary hyperten-
sion. Br J Clin Pharmacol 2005;60:107–112.
96. Burgess G, Hoogkamer H, Collings L, Dingemanse J. Mutual pharmacokinetic
interactions between steady-state bosentan and sildenaﬁl. Eur J Clin Pharmacol
2008;64:43–50.
97. Humbert M, Segal ES, Kiely DG, Carlsen J, Schwierin B, Hoeper MM. Results of
European post-marketing surveillance of bosentan in pulmonary hypertension.
Eur Respir J 2007;30:338–344.
98. Committee for Proprietary Medicinal Products (CPMP). Tracleer(R).
Public Assessment Report. Summary of Product Characteristics. Scientiﬁc Dis-
cussion. http://www.emea.europa.eu/humandocs/Humans/EPAR/tracleer/tra-
cleer.htm (28 May 2008).
99. Committee for Proprietary Medicinal Products (CPMP) 2006. Thelin(R). Public
Assessment Report. Summary of Product Characteristics. Scientifc Discussion.
http://www.emea.europa.eu/humandocs/Humans/EPAR/thelin/thelin.htm (28
May 2008).
100. Macchia A, Marchioli R, Marﬁsi R, Scarano M, Levantesi G, Tavazzi L, Tognoni G.
A meta-analysis of trials of pulmonary hypertension: a clinical condition looking
for drugs and research methodology. Am Heart J 2007;153:1037–1047.
101. Kiowski W, Sutsch G, Hunziker P, Muller P, Kim J, Oechslin E, Schmitt R, Jones R,
Bertel O. Evidence for endothelin-1-mediated vasoconstriction in severe
chronic heart failure. Lancet 1995;346:732–736.
102. Su ¨tsch G, Kiowski W, Yan XW, Hunziker P, Christen S, Strobel W, Kim JH,
Rickenbacher P, Bertel O. Short-term oral endothelin-receptor antagonist
therapy in conventionally treated patients with symptomatic severe chronic
heart failure. Circulation 1998;98:2262–2268.
103. Weber C, Schmitt R, Birnboeck H, Hopfgartner G, van Marle SP, Peeters PA,
Jonkman JH, Jones CR. Pharmacokinetics and pharmacodynamics of the
endothelin-receptor antagonist bosentan in healthy human subjects. Clin
Pharmacol Ther 1996;60:124–137.
104. Weber C, Banken L, Birnboeck H, Schulz R. Effect of the endothelin-receptor
antagonist bosentan on the pharmacokinetics and pharmacodynamics of
warfarin. J Clin Pharmacol 1999;39:847–854.
105. Williamson DJ, Wallman LL, Jones R, Keogh AM, Scroope F, Penny R, Weber C,
Macdonald PS. Hemodynamic effects of bosentan, an endothelin receptor
antagonist, in patients with pulmonary hypertension. Circulation 2000;102:
411–418.
106. Hiramoto Y, Shioyama W, Kuroda T, Masaki M, Sugiyama S, Okamoto K,
Hirota H, Fujio Y, Hori M, Yamauchi-Takihara K. Effect of bosentan on plasma
endothelin-1 concentration in patients with pulmonary arterial hypertension.
Circ J 2007;71:367–369.
107. Vatter H, Seifert V. Ambrisentan, a non-peptide endothelin receptor antagonist.
Cardiovasc Drug Rev 2006;24:63–76.
108. Olschewski H, Galie N, Ghofrani H et al. Ambrisentan improves exercise
capacity and time to clinical worsening in patients with pulmonary arterial hyper-
tension: Results of the ARIES-2 study [abstract]. Proc Am Thorac Soc 2006;3:A728.
The above article uses a new reference style being piloted by the
EHJ that shall soon be used for all articles.
C.F. Opitz et al. 1948